File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1021/acs.molpharmaceut.0c01242
- Scopus: eid_2-s2.0-85107902693
- PMID: 34014665
- WOS: WOS:000661309800009
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Optimization of PEGylated KL4 Peptide for siRNA Delivery with Improved Pulmonary Tolerance
Title | Optimization of PEGylated KL4 Peptide for siRNA Delivery with Improved Pulmonary Tolerance |
---|---|
Authors | |
Keywords | lung surfactant monodisperse PEG PEGylation peptide pulmonary delivery |
Issue Date | 2021 |
Publisher | American Chemical Society. The Journal's web site is located at http://pubs.acs.org/journals/mpohbp/index.html |
Citation | Molecular Pharmaceutics, 2021, v. 18 n. 6, p. 2218-2232 How to Cite? |
Abstract | Pulmonary delivery of small interfering RNA (siRNA) is a promising therapeutic strategy for treating various respiratory diseases but an effective carrier for the delivery of siRNA into the cells of the lungs and a robust gene-silencing effect is still lacking. Previously, we reported that the KL4 peptide, a synthetic cationic peptide with a repeating KLLLL sequence, can mediate effective siRNA transfection in lung epithelial cells but its high hydrophobic leucine content, and hence poor water solubility, limits its application as a delivery vector. Here, we show that the covalent attachment of monodisperse poly(ethylene glycol) (PEG) improves the solubility of KL4 and the uptake of its complex with siRNA into lung epithelial cells, such that very robust silencing is produced. All PEGylated KL4 peptides, with PEG length varying between 6 and 24 monomers, could bind and form nanosized complexes with siRNA, but the interaction between siRNA and peptides became weaker as the PEG chain length increased. All PEGylated KL4 peptides exhibited satisfactory siRNA transfection efficiency on three human lung epithelial cell lines, including A549 cells, Calu-3 cells, and BEAS-2B cells. The PEG12KL4 peptide, which contains 12 monomers of PEG, was optimal for siRNA delivery and also demonstrated a low risk of inflammatory response and toxicity in vivo following pulmonary administration. |
Persistent Identifier | http://hdl.handle.net/10722/300697 |
ISSN | 2023 Impact Factor: 4.5 2023 SCImago Journal Rankings: 0.940 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Qiu, Y | - |
dc.contributor.author | Clarke, M | - |
dc.contributor.author | Wan, TLL | - |
dc.contributor.author | Lo, JCK | - |
dc.contributor.author | Mason, AJ | - |
dc.contributor.author | Lam, JKW | - |
dc.date.accessioned | 2021-06-18T14:55:45Z | - |
dc.date.available | 2021-06-18T14:55:45Z | - |
dc.date.issued | 2021 | - |
dc.identifier.citation | Molecular Pharmaceutics, 2021, v. 18 n. 6, p. 2218-2232 | - |
dc.identifier.issn | 1543-8384 | - |
dc.identifier.uri | http://hdl.handle.net/10722/300697 | - |
dc.description.abstract | Pulmonary delivery of small interfering RNA (siRNA) is a promising therapeutic strategy for treating various respiratory diseases but an effective carrier for the delivery of siRNA into the cells of the lungs and a robust gene-silencing effect is still lacking. Previously, we reported that the KL4 peptide, a synthetic cationic peptide with a repeating KLLLL sequence, can mediate effective siRNA transfection in lung epithelial cells but its high hydrophobic leucine content, and hence poor water solubility, limits its application as a delivery vector. Here, we show that the covalent attachment of monodisperse poly(ethylene glycol) (PEG) improves the solubility of KL4 and the uptake of its complex with siRNA into lung epithelial cells, such that very robust silencing is produced. All PEGylated KL4 peptides, with PEG length varying between 6 and 24 monomers, could bind and form nanosized complexes with siRNA, but the interaction between siRNA and peptides became weaker as the PEG chain length increased. All PEGylated KL4 peptides exhibited satisfactory siRNA transfection efficiency on three human lung epithelial cell lines, including A549 cells, Calu-3 cells, and BEAS-2B cells. The PEG12KL4 peptide, which contains 12 monomers of PEG, was optimal for siRNA delivery and also demonstrated a low risk of inflammatory response and toxicity in vivo following pulmonary administration. | - |
dc.language | eng | - |
dc.publisher | American Chemical Society. The Journal's web site is located at http://pubs.acs.org/journals/mpohbp/index.html | - |
dc.relation.ispartof | Molecular Pharmaceutics | - |
dc.rights | This document is the Accepted Manuscript version of a Published Work that appeared in final form in [JournalTitle], copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see [insert ACS Articles on Request author-directed link to Published Work, see http://pubs.acs.org/page/policy/articlesonrequest/index.html]. | - |
dc.subject | lung surfactant | - |
dc.subject | monodisperse PEG | - |
dc.subject | PEGylation | - |
dc.subject | peptide | - |
dc.subject | pulmonary delivery | - |
dc.title | Optimization of PEGylated KL4 Peptide for siRNA Delivery with Improved Pulmonary Tolerance | - |
dc.type | Article | - |
dc.identifier.email | Qiu, Y: qiuysh@hku.hk | - |
dc.identifier.email | Wan, TLL: leonwan.cpos@hku.hk | - |
dc.identifier.email | Lo, JCK: jasonlck@hku.hk | - |
dc.identifier.email | Lam, JKW: jkwlam@hku.hk | - |
dc.identifier.authority | Lam, JKW=rp01346 | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1021/acs.molpharmaceut.0c01242 | - |
dc.identifier.pmid | 34014665 | - |
dc.identifier.scopus | eid_2-s2.0-85107902693 | - |
dc.identifier.hkuros | 322806 | - |
dc.identifier.volume | 18 | - |
dc.identifier.issue | 6 | - |
dc.identifier.spage | 2218 | - |
dc.identifier.epage | 2232 | - |
dc.identifier.isi | WOS:000661309800009 | - |
dc.publisher.place | United States | - |